Calamos Advisors LLC Purchases 10,523 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Calamos Advisors LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 86.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 22,658 shares of the biopharmaceutical company’s stock after acquiring an additional 10,523 shares during the quarter. Calamos Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $16,140,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on REGN. Bank of America reiterated an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Wells Fargo & Company decreased their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Finally, Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Stock Down 0.9 %

Shares of REGN stock opened at $666.85 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $663.43 and a 52-week high of $1,211.20. The stock has a market cap of $73.28 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 1.60 and a beta of 0.08. The firm’s 50-day moving average is $720.81 and its 200-day moving average is $921.72. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.